X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1399) 1399
Publication (71) 71
Book Review (5) 5
Newsletter (4) 4
Book Chapter (3) 3
Conference Proceeding (3) 3
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (886) 886
animals (823) 823
oncology (570) 570
radiation-sensitizing agents - pharmacokinetics (510) 510
mice (496) 496
female (475) 475
radiation-sensitizing agents - therapeutic use (441) 441
male (413) 413
radiation-sensitizing agents - pharmacology (386) 386
index medicus (358) 358
radiology, nuclear medicine & medical imaging (330) 330
radiotherapy (321) 321
radiation-sensitizing agents - administration & dosage (319) 319
cancer (261) 261
combined modality therapy (220) 220
cell line, tumor (192) 192
radiation (180) 180
middle aged (172) 172
tumors (167) 167
aged (154) 154
rats (154) 154
tissue distribution (151) 151
chemotherapy (146) 146
cell survival - drug effects (140) 140
adult (135) 135
therapy (135) 135
pharmacokinetics (133) 133
radiosensitization (133) 133
dose-response relationship, drug (131) 131
neoplasms - radiotherapy (129) 129
mice, nude (126) 126
pharmacology & pharmacy (126) 126
radiation-sensitizing agents - metabolism (120) 120
photodynamic therapy (114) 114
radiosensitizers (114) 114
toxicity (113) 113
drugs (112) 112
mice, inbred balb c (112) 112
photochemotherapy (112) 112
radiation-sensitizing agents - adverse effects (110) 110
biochemistry & molecular biology (105) 105
neoplasm transplantation (104) 104
cell survival - radiation effects (102) 102
radiation, thermal, and other environ. pollutant effects on living orgs. and biol. mat (101) 101
radiation-sensitizing agents - toxicity (101) 101
tumor cells, cultured (100) 100
biophysics (99) 99
misonidazole (99) 99
neoplasms (98) 98
neoplasms - drug therapy (98) 98
cells (96) 96
hypoxia (96) 96
time factors (95) 95
apoptosis (94) 94
mice, inbred c3h (93) 93
radiation-therapy (93) 93
etanidazole (91) 91
antineoplastic agents - therapeutic use (90) 90
organic compounds (89) 89
misonidazole - analogs & derivatives (87) 87
treatment outcome (87) 87
radiology and nuclear medicine (86) 86
care and treatment (84) 84
dose-response relationship, radiation (84) 84
heterocyclic compounds (83) 83
nitroimidazoles - pharmacokinetics (82) 82
radiation-sensitizing agents (82) 82
radiotherapy dosage (80) 80
brain neoplasms - radiotherapy (79) 79
organic nitrogen compounds (76) 76
irradiation (75) 75
radiation therapy (75) 75
radiology (75) 75
radiation-sensitizing agents - chemistry (74) 74
hematology, oncology and palliative medicine (73) 73
in-vitro (73) 73
antineoplastic agents - pharmacokinetics (70) 70
carcinoma (70) 70
radiosensitizer (70) 70
antineoplastic agents - pharmacology (68) 68
diseases (68) 68
clinical trials as topic (67) 67
cricetinae (67) 67
apoptosis - drug effects (66) 66
kinetics (65) 65
medicine (65) 65
oxygen (65) 65
research (65) 65
squamous-cell carcinoma (65) 65
xenograft model antitumor assays (65) 65
azoles (64) 64
carcinoma, squamous cell - radiotherapy (64) 64
biology (63) 63
neoplasms - metabolism (63) 63
phenylalanine - analogs & derivatives (63) 63
antineoplastic agents - administration & dosage (60) 60
cell line (60) 60
imidazoles (60) 60
neoplasms, experimental - drug therapy (60) 60
nitroimidazoles - pharmacology (60) 60
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1373) 1373
Japanese (10) 10
Russian (8) 8
Chinese (7) 7
French (5) 5
German (4) 4
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Advanced Materials, ISSN 0935-9648, 06/2014, Volume 26, Issue 21, pp. 3433 - 3440
MoS2 nanosheets functionalized with poly­ethylene glycol are for the first time used as a multifunctional drug delivery system with high drug loading... 
MoS2 nanosheet | combination therapy | drug delivery | 2D nanostructure | photothermal therapy | GRAPHENE OXIDE | CELLS | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | METAL DICHALCOGENIDE NANOSHEETS | NANOSCIENCE & NANOTECHNOLOGY | TUMOR VASCULATURE | CHEMISTRY, MULTIDISCIPLINARY | NANOPARTICLES | THERAPY | NANOGRAPHENE | CHEMISTRY | NANOTUBES | Molybdenum - chemistry | Drug Carriers - adverse effects | Porphyrins - administration & dosage | Humans | Polyethylene Glycols - adverse effects | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Porphyrins - pharmacokinetics | Radiation-Sensitizing Agents - pharmacokinetics | Drug Carriers - chemistry | Phototherapy - methods | Molybdenum - adverse effects | Radiation-Sensitizing Agents - administration & dosage | Disulfides - chemistry | Camptothecin - administration & dosage | Female | Nanostructures - adverse effects | Antineoplastic Agents - pharmacokinetics | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Cell Survival - drug effects | KB Cells | Disulfides - adverse effects | Combined Modality Therapy | Disulfides - chemical synthesis | Doxorubicin - pharmacokinetics | Mammary Neoplasms, Experimental - therapy | Pilot Projects | Animals | Cell Line, Tumor | Nanostructures - chemistry | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | HeLa Cells | Drugs | Chemotherapy | Drug delivery systems | Vehicles | Cancer
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 3/2017, Volume 56, Issue 3, pp. 235 - 250
Afatinib is an oral, irreversible ErbB family blocker that covalently binds to the kinase domains of epidermal growth factor receptor (EGFR), human EGFRs (HER)... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | CELL LUNG-CANCER | BREAST-CANCER | RANDOMIZED PHASE-3 TRIAL | BIBW 2992 | ADVANCED SOLID TUMORS | FACTOR RECEPTOR MUTATIONS | ACQUIRED-RESISTANCE | PHARMACOLOGY & PHARMACY | OPEN-LABEL | ERBB FAMILY BLOCKER | I DOSE-ESCALATION | Neoplasms - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Kidney - drug effects | Humans | Liver - metabolism | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Quinazolines - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Radiation-Sensitizing Agents - pharmacokinetics | Neoplasms - drug therapy | Radiation-Sensitizing Agents - therapeutic use | ATP-Binding Cassette, Sub-Family B, Member 1 - agonists | Kidney - metabolism | Receptor, Epidermal Growth Factor - metabolism | Animals | Liver - drug effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Drug Interactions - physiology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Binding - physiology | Pharmacology | Research | Bioavailability | Pharmacokinetics | Analysis | Cytochrome | Plasma | Lung cancer | Breast cancer | Metastasis | Permeability | Kinases | Cancer therapies | Studies | Chemotherapy | Epidermal growth factor | Mutation | Drug dosages | Binding sites | Tumors | Review
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2010, Volume 16, Issue 20, pp. 4946 - 4957
Journal Article
International Journal of Cancer, ISSN 0020-7136, 03/2015, Volume 136, Issue 6, pp. 1445 - 1457
Journal Article
Drugs, ISSN 0012-6667, 9/2013, Volume 73, Issue 13, pp. 1503 - 1515
Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | CELL LUNG-CANCER | TRIAL | GROWTH-FACTOR RECEPTOR | BIBW 2992 | TYROSINE KINASE | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | ERBB FAMILY BLOCKER | PHASE-I | I DOSE-ESCALATION | ORAL TREATMENT | Chemoradiotherapy - adverse effects | Receptor, ErbB-2 - genetics | United States | Humans | Lung Neoplasms - metabolism | Receptor, ErbB-2 - metabolism | Quinazolines - pharmacokinetics | Lung Neoplasms - pathology | Neoplasm Proteins - antagonists & inhibitors | Drug Approval | Protein Kinase Inhibitors - adverse effects | Neoplasm Proteins - metabolism | Radiation-Sensitizing Agents - pharmacokinetics | Radiation-Sensitizing Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Lung - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Neoplasm Proteins - genetics | United States Food and Drug Administration | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Lung - pathology | Molecular Targeted Therapy - adverse effects | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - therapy | Radiation-Sensitizing Agents - adverse effects | Carcinoma, Non-Small-Cell Lung - therapy | Animals | European Union | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Lung - drug effects | Quinazolines - adverse effects | Taiwan | Mutation | Neoplasm Staging | Drug approval
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2015, Volume 11, Issue 5, pp. 1277 - 1283
Journal Article
Theranostics, ISSN 1838-7640, 2016, Volume 6, Issue 4, pp. 456 - 469
Journal Article
Trends in Biotechnology, ISSN 0167-7799, 2003, Volume 21, Issue 5, pp. 210 - 216
The carotenoid pigment astaxanthin has important applications in the nutraceutical, cosmetics, food and feed industries. Haematococcus pluvialis is the richest... 
BETA-CAROTENE | OXIDATIVE STRESS | IMMUNOMODULATING ACTIONS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NATURALLY-OCCURRING XANTHOPHYLLS | T-DEPENDENT ANTIGENS | MACULAR DEGENERATION | DIETARY ANTIOXIDANTS | CORONARY HEART-DISEASE | VITRO ANTIBODY-PRODUCTION | VITAMIN-A | Neurodegenerative Diseases - diet therapy | Xanthophylls | Species Specificity | Antioxidants - metabolism | Humans | Nutritional Physiological Phenomena | Biological Availability | beta Carotene - pharmacokinetics | Radiation-Sensitizing Agents - pharmacokinetics | Blindness - prevention & control | Chlorophyta - metabolism | Adjuvants, Immunologic - pharmacokinetics | Radiation-Sensitizing Agents - therapeutic use | Inflammation - diet therapy | Radiation-Sensitizing Agents - administration & dosage | Adjuvants, Immunologic - metabolism | Adjuvants, Immunologic - therapeutic use | Chlorophyta - classification | Macular Degeneration - prevention & control | Administration, Oral | beta Carotene - administration & dosage | beta Carotene - metabolism | Chlorophyta - chemistry | Antioxidants - therapeutic use | Arteriosclerosis - prevention & control | Neoplasms - diet therapy | Photosensitivity Disorders - prevention & control | Radiation-Sensitizing Agents - metabolism | Antioxidants - administration & dosage | Diet Therapy - methods | Antioxidants - pharmacokinetics | beta Carotene - analogs & derivatives | Macular degeneration | Antioxidants | Aging | Lipids | Fish
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2016, Volume 94, Issue 1, pp. 189 - 205
Journal Article
Cancer Research, ISSN 0008-5472, 05/2006, Volume 66, Issue 10, pp. 5354 - 5362
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 04/2016, Volume 228, pp. 141 - 149
Journal Article